Education, Science, Technology, Innovation and Life
Open Access
Sign In

The predictive effect of serum HBV-RNA and HBcrAg on the disease changes in patients with chronic hepatitis B

Download as PDF

DOI: 10.23977/medsc.2023.040108 | Downloads: 8 | Views: 383

Author(s)

Xirong Li 1, Zhuoran Ji 1, Jie Zhang 2, Xiaoni Kou 2

Affiliation(s)

1 Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712000, China
2 Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712000, China

Corresponding Author

Xirong Li

ABSTRACT

Chronic hepatitis B has not been cured until now because covalently closed circular DNA (cccDNA) in the liver cannot be completely eradicated. In the era of continuous medical innovation, nucleoside (acid) analogues (NAs) can make serum HBV deoxyribonucleic acid (HBV-DNA) reach the detection limit, but only represents the interruption of virus replication. Liver biopsy is the gold standard for the expression of cccDNA transcriptional activity. However, it is an invasive detection method, and its clinical popularity is far from enough. Therefore, an alternative and accurate serum marker is needed. Hbv-rna (hepatitis B virus ribonucleic acid), in the form of virions containing pregenomic RNA (pgRNA), can be used to predict early liver fibrosis, viral rebound after NA withdrawal, and to evaluate the efficacy of new antiviral drugs. HBcrAg (Hepatitis B core-associated antigen) is a serum complex viral protein that helps predict HBV reactivation, the risk of hepatocellular carcinoma, the timing of safe drug withdrawal after NA treatment, and HBeAg conversion. Both are new surveillance tools. This article reviews the predictive significance of HBcrAg and HBV-RNA in the development of disease.

KEYWORDS

Chronic hepatitis B, HBcrAg, HBV-RNA, intrahepatic cccDNA

CITE THIS PAPER

Xirong Li, Zhuoran Ji, Jie Zhang, Xiaoni Kou, The predictive effect of serum HBV-RNA and HBcrAg on the disease changes in patients with chronic hepatitis B. MEDS Clinical Medicine (2023) Vol. 4: 46-52. DOI: http://dx.doi.org/10.23977/medsc.2023.040108.

REFERENCES

[1] Allweiss L, Volz T, Giersch K, et al. Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo. Gut. 2018 Mar; 67(3): 542-552. 
[2] YUEN MF, CHEN DS, DUSHEIKO GM, etal. Hepatitis B virus infection [J] Nat Rev Dis Primers. 2018 Jun 7;4:18036.  
[3] Thiele M, Gluud LL, Dahl EK, et al. Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis B: systematic review and meta-analysis. BMJ Open. 2013 Aug 14; 3(8): e003265. 
[4] Gordon SC, Lamerato LE, Rupp LB, et al. 2014. Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population. Clin. Gas-troenterol. Hepatol. 12: 885-93.
[5] Papatheodoridis GV, Idilman R, Dalekos GN, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology. 2017 Nov; 66(5): 1444-1453. 
[6] Yang HC, Chen PJ. The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA. Virus Res.2018 Jan 15; 244: 304-310. 
[7] Mak LY, Seto WK, Fung J, Yuen MF. Novel developments of hepatitis B: treatment goals, agents and monitoring tools. Expert Rev Clin Pharmacol. 2019 Feb; 12(2): 109-120. 
[8] Chen Huan, Yang Yanqing, Chu Jun et al. Research progress of HBV persistent infection and its mechanism [J]. Journal of Clinical Hepatobiliary diseases, 2020, 36(1): 174-177.
[9] Yang HC, Chen PJ. The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA.Virus Res.2018 Jan 15; 244: 304-310.
[10] Wang J, Yu Y, Li G, et al. Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients. J Hepatol. 2017; S0168-8278(17) 32261-4.
[11] Erken R, Zaaijer HL, Willemse SB, et al. Hepatitis B core related antigen in relation to intrahepatic and circulating viral markers, before and after combination therapy. Ann Hepatol. 2021 Dec; 26: 100540.
[12] Wang Guiqiang, Duan Zhongping, Wang Fusheng, et al. Guidelines for the prevention and treatment of chronic hepatitis B (2019 edition) [J]. Chin J Hepatology, 20,23(01): 9-32. (in Chinese)
[13] Kaewdech A, Tangkijvanich P, Sripongpun P, et al. Hepatitis B surface antigen, core-related antigen and HBV RNA: Predicting clinical relapse after NA therapy discontinuation. Liver Int.2020 Dec; 40(12): 2961-2971. 
[14] Yuen MF, Kim DJ, Weilert F, etal. NVR3-778, a first-in-class HBV core inhibitor, alone and in combination with Peg-interferon (Pe-gIFN), in treatment-naive HBeAg-positive patients: early reduc-tions in HBV DNA and HBeAg. J Hepatol 2016; 64:S210-S211.
[15] Yuen MF, Coffin CS, Elkhashab SG, et al. SB 9200 an oral selective immunomodulator is safe and efficacious in treatment-naive, non-cirrhotic HBV patients: results from cohort 1 of the ACHIEVE trial. Hepatology 2017; 66: 22-23A.
[16] Wang J, Yu Y, Li G, et al. Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients. J Hepatol. 2017 Sep 21: S0168-8278 (17) 32261-4.
[17] Yuan Y H, HBeAg positive and negative patients with serum HBVRNA level and Hepatitis B related liver fibrosis analysis [J]. Chinese Modern Doctors. 2021.59 (8): 1-5.
[18] Jiang Y, Han Q, Zhao H, Zhang J. The Mechanisms of HBV-Induced Hepatocellular Carcinoma.J Hepatocell Carcinoma.2021 May 20;8:435-450. 
[19] Ma G,  Lou B,  Lv F, et al. HBcrAg and pg RNA and the therapeutic effect in HBeAg-positive patients receiving anti-viral therapy, baseline serum HBV-RNA is a powerful predictor of response.[J]. Journal of viral hepatitis, 2020, 27(8):837-846.
[20] Tada T, Kumada T, Toyoda H, et al. HBcrAg predicts hepatocellular carcinoma development: An analysis using time-dependent receiver operating characteristics. J Hepatol.2016 Jul;65(1):48-56.
[21] Kumada T, Toyoda H, Tada T, et al. Effect of nucleos (t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. J Hepatol. 2013 Mar; 58(3): 427-433. 
[22] Caviglia GP, Abate ML, Noviello D, et al. Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon-α. Hepatol Res. 2017 Jul; 47(8): 747-754.
[23] Guo L, Wang D, Ouyang X, et al. Recent Advances in HBV Reactivation Research. Biomed Res Int. 2018 Dec 26;2018:2931402. 
[24] Seto WK, Wong DK, Chan TS, et al. Association of hepatitis B core-related antigen with hepatitis B virus reactivation in occult viral carriers undergoing high-risk immunosuppressive therapy. Am J Gastroenterol 2016;111:1788-1795. 
[25] Lu Fengmin, Dou Xiaoguang, Zhang Wenhong, et al. Clinical significance of serum HBV-RNA detection in chronic hepatitis B patients [J]. Journal of Hepatobiliary Diseases, 2018,34 (5):934-938.
[26] Mak LY, Seto WK, Fung J, Yuen MF. New Biomarkers of Chronic Hepatitis B. Gut Liver. 2019 Nov 15; 13(6): 589-595.  
[27] Matsumoto, A. Tanaka, E. Minami, M. et al. Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy. Hepatol. Res. 2007, 37,661-666. 
[28] Wang B, Carey I, Bruce M, et al. HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos (t)ide analogues. J Viral Hepat.2018 Aug;25(8):886-893.  
[29] Ma G, Lou B, Lv F, et al. HBcrAg and pg RNA and the therapeutic effect in HBeAg-positive patients receiving anti-viral therapy, baseline serum HBV-RNA is a powerful predictor of response. J Viral Hepat. 2020 Aug; 27(8): 837-846. 
[30] Shi L, Zhou B, Valdes J D, et al. Serum HBV RNA: a New Potential Biomarker for Chronic Hepatitis B Virus Infection [J]. Hepatology, 2018, 69(4).

Downloads: 3912
Visits: 170395

Sponsors, Associates, and Links


All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.